Adma Biologics Inc [ADMA] stock is trading at $20.72, up 2.68%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADMA shares have gain 4.81% over the last week, with a monthly amount glided 12.73%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
Adma Biologics Inc [ADMA] stock has fluctuated between $3.06 and $20.58 over the past year. Currently, Wall Street analysts expect the stock to reach $9.25 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $20.72 at the most recent close of the market. An investor can expect a potential drop of -55.36% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
Adma Biologics Inc [NASDAQ:ADMA] reported sales of 330.24M for the trailing twelve months, which represents a growth of 78.29%. Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at 0.25%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.22 and Total Capital is 0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.21 points at the first support level, and at 19.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.07, and for the 2nd resistance point, it is at 21.43.
Ratios To Look Out For
For context, Adma Biologics Inc’s Current Ratio is 6.87. On the other hand, the Quick Ratio is 2.80, and the Cash Ratio is 2.0. Considering the valuation of this stock, the price to sales ratio is 14.62, the price to book ratio is 25.65 and price to earnings (TTM) ratio is 147.37.
Transactions by insiders
Recent insider trading involved Guiheen Lawrence P., Director, that happened on Sep 09 ’24 when 9000.0 shares were sold. Director, Guiheen Lawrence P. completed a deal on Sep 09 ’24 to buy 9000.0 shares. Meanwhile, COO and SVP, Compliance Kestenberg-Messina Kaitlin M. sold 24150.0 shares on Aug 30 ’24.
